z-logo
Premium
Two imidazoquinoxaline ligands for the benzodiazepine site sharing a second low affinity site on rat GABA A receptors but with the opposite functionality
Author(s) -
Im Haesook K.,
Bin Im Wha,
Pregenzer Jeffrey F.,
Stratman Nancy C.,
VonVoigtlander Philip F.,
Jon Jacobsen E.
Publication year - 1998
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0701763
Subject(s) - allosteric regulation , chemistry , substituent , binding site , ligand (biochemistry) , allosteric modulator , receptor , stereochemistry , gabaa receptor , biophysics , biochemistry , biology
Imidazoquinoxaline PNU‐97775 and imidazoquinoline PNU‐101017 are benzodiazepine site ligands with a second low affinity binding site on GABA A receptors, the occupancy of which at high drug concentrations reverses their positive allosteric activity via the benzodiazepine site, and may potentially minimize abuse liability and physical dependence. In this study we discovered, with two imidazoquinoxaline analogues, that the functionality of the second site was altered by the nitrogen substituent on the piperazine ring moiety: PNU‐100076 with a hydrogen substituent on the position produced a negative allosteric effect via the second low affinity site, like the parent compounds, while PNU‐100079 with a trifluoroethyl substituent produced a positive allosteric response. These functional characteristics were monitored with Cl − currents measurements in cloned rat αxβ2γ2 subtypes of GABA A receptors expressed in human embryonic kidney 293 cells, and further confirmed in rat cerebrocortical membranes containing complex subtypes of GABA A receptors with binding of [ 35 S]‐TBPS, which is a high affinity ligand specific for GABA A receptors with exquisite sensitivity to allosteric modulations. This structure‐functional relationship could be exploited to further our understanding of the second allosteric site of imidazoquinoxaline analogues, and to develop more effective benzodiazepine site ligands without typical side effects associated with those currently available on the market.British Journal of Pharmacology (1998) 123 , 1490–1494; doi: 10.1038/sj.bjp.0701763

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here